YG PRESS NEWS – Revolutionizing healthcare: the point-of-need microfluidic testing are a game-changer
Will the molecular diagnostics be the driver of the microfluidics PoNT market to US$16.2 billion in 2028?
- The PoN microfluidic testing market is expected to reach US$16.2 billion, with a 7.0% CAGR22-28.
- COVID-19 was an accelerator of PoNT solutions adoption.
- Almost 91% of the PoN microfluidic testing market (in value) is held by ten players.
- Innovations in PoNT to meet market demands for accuracy, speed, ease of use, and affordability.
According to Yole Intelligence, part of Yole group, in the Microfluidics based Point-of-Need Testing 2023 report, PoN microfluidic-based tests have gained significant traction in hospitals, emergency rooms, and low-income countries. The year 2022 witnessed a remarkable milestone with the shipment of 631 million modules, and this figure will escalate to 886 million by 2028, exhibiting a CAGR of 5.8% from 2022 to 2028. Moreover, in terms of revenue at the module level, the global market reached a substantial value of approximately US$10.8 billion in 2022. Looking ahead, Yole Intelligence’s forecasts indicate a robust growth trajectory, with the market poised to expand to US$16.2 billion by 2028, reflecting a CAGR of 7.0% from 2022 to 2028. These revenue projections underscore the immense economic potential and opportunities associated with PoN microfluidic-based testing in the healthcare sector… For more information about this analysis, please contact us!
